Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

MM - 338

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani

Poster Presenter: Saad Z Usmani

Thumbnail for Daratumumab-Based Treatment Strategies with Daratumumab-Lenalidomide Maintenance vs Lenalidomide Maintenance in Transplant Eligible NDMM: A Systematic Review and Meta-Analysis

MM - 1453

Daratumumab-Based Treatment Strategies with Daratumumab-Lenalidomide Maintenance vs Lenalidomide Maintenance in Transplant Eligible NDMM: A Systematic Review and Meta-Analysis

Devesh Amin

Previous 1...31 32 33 34 35 36 37...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Poster Presenter: Devesh Amin

Thumbnail for Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

CLL - 429

Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

Michael Tees

Poster Presenter: Michael Tees

$Thumbnail for DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma$

CLL - 432

DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Megan Wang

Poster Presenter: Megan Wang

Thumbnail for Declining but Unequal: Trends and Sociodemographic Disparities in Acute Myeloid Leukemia Mortality in the United States, 2018-2024

AML - 402

Declining but Unequal: Trends and Sociodemographic Disparities in Acute Myeloid Leukemia Mortality in the United States, 2018-2024

Priscilla Kabutey

Poster Presenter: Priscilla Kabutey

Thumbnail for Declining Population-Level Infection-Attributed Mortality in Chronic Lymphocytic Leukemia in the United States, 1999-2020: A CDC WONDER Analysis

CLL - 370

Declining Population-Level Infection-Attributed Mortality in Chronic Lymphocytic Leukemia in the United States, 1999-2020: A CDC WONDER Analysis

Anas Mardini

Poster Presenter: Anas Mardini

Thumbnail for Deconvolution of Peripheral Blood Transcriptomes to Evaluate Immune Profiles Associated With Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Machine Learning-Driven Study

ALL - 486

Deconvolution of Peripheral Blood Transcriptomes to Evaluate Immune Profiles Associated With Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Machine Learning-Driven Study

Fatima Aslam

Poster Presenter: Fatima Aslam

Thumbnail for Deep molecular response duration predicts treatment-free remission in CML rescued after resistance, warning or major molecular response

CML - 310

Deep molecular response duration predicts treatment-free remission in CML rescued after resistance, warning or major molecular response

Delphine Rea

Poster Presenter: Delphine Rea

Thumbnail for Deep Remission, Delayed Immunity: Prospective Characterization of Normal B-Cell Reconstitution After Venetoclax Based Therapy in CLL and its Implications for Vaccination.

CLL - 880

Deep Remission, Delayed Immunity: Prospective Characterization of Normal B-Cell Reconstitution After Venetoclax Based Therapy in CLL and its Implications for Vaccination.

Chantal Saberian

Poster Presenter: Chantal Saberian

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors